Regarding toxicity of the multimodal treatment, a systematic review and meta-analysis including 20 clinical trials and a total of 2027 patients with NSCLC of any tumor stage showed that immunotherapy using PD-1/PD-L1 inhibitors and RT did not increase the serious adverse event rates (≥grade 3) compared with non-combination therapy [16]. The gene discussed is CD274; the disease is neoplasm.